Pregnancy Complications Clinical Trial
— RESeTOfficial title:
Writing to Reduce Stress in Expectant Moms: The RESet Study
Verified date | September 2022 |
Source | University of North Carolina, Chapel Hill |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Purpose: The investigators hypothesize that exposure to chronic environmental stress is a risk factor for adverse pregnancy outcomes related to preterm birth and preeclampsia among high-risk pregnant women. Additionally, the investigators hypothesize that women can be screened for high levels of environmental stress through the perceived stress scale, and therapeutic writing can be used as a low-resource intervention to help decrease maternal perceived stress and inflammation - measured through analysis of maternal serum and placental samples. Participants: Pregnant women at high risk for adverse pregnancy outcomes, including pre-eclampsia and preterm birth, enrolled in prenatal care at UNC will be recruited for participation Procedures: Using results from the perceived stress scale, the investigators will identify women who screen positive for high environmental stress. Women meeting inclusion criteria will be contacted for possible participation at regularly scheduled prenatal visits. Women who are enrolled will be randomized to generalized writing prompts, therapeutic writing prompts, or no writing during their pregnancy to be administered at each prenatal visit. Maternal blood sample for biochemical markers of stress and gene expression will be obtained at the initial visit; a followup blood sample will be obtained later in pregnancy, and a small portion of the placenta saved at delivery. Delivery outcomes will be obtained through medical record review.
Status | Active, not recruiting |
Enrollment | 15 |
Est. completion date | December 22, 2024 |
Est. primary completion date | December 22, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - Women will be prospectively recruited. 1. Gestational age: All women presenting for prenatal care at 8.0 to 19.9 weeks' gestation through the UNC-Hospitals High Risk obstetrics clinic will be screened for high risk of an adverse pregnancy outcome (ex: preterm birth or pre-eclampsia) through review of their medical record. 2. Singleton viable intrauterine pregnancy, with dating confirmed by ultrasound or plans for ultrasound to confirm dating prior to study enrollment 3. No structural abnormalities or aneuploidy 4. Ability to communicate in and provide consent in English 5. Women with at least ONE of the following high risk criteria: a. Short cervix by endovaginal ultrasound, measuring <25mm b. Prior spontaneous preterm birth 16.0 - 33.9 weeks' gestation i. Documentation of the prior spontaneous preterm birth in the patient's medical records is desirable but is not required for eligibility. ii. The previous preterm delivery cannot be an antepartum stillbirth but an intrapartum stillbirth (due to extreme prematurity) is allowable. c. Chronic hypertension on medications d. History of pre-eclampsia requiring delivery <37 weeks' gestation, or history of severe pre-eclampsia delivering at any gestational age OR 6. Women with at least TWO of the following moderate risk criteria: 1. Prior preterm birth 34.0-36.9 weeks 2. Chronic hypertension not requiring medications 3. History of term pre-eclampsia 4. Type II diabetes on insulin 5. Obesity with a BMI >30 6. Smoking during pregnancy 7. Black race 8. Maternal age <18 years old or >40 years old 9. Nulliparous 10. Uninsured, or medicaid insurance 7. Women who meet at least one major or 2 minor inclusion criteria along with the other criteria above will then be screened for high levels of acute and chronic stress and trauma using the Perceived Stress questionnaire to determine final eligibility for the study Exclusion Criteria: 1. Persistent Illicit drug or alcohol abuse during current pregnancy >12 weeks. Use of tobacco and/or marijuana is not an exclusion. Methadone or suboxone use in an approved treatment program is not an exclusion. 2. Prior preterm birth or preeclampsia was in a pregnancy complicated by fetal aneuploidy or major congenital fetal anomalies in the absence of another pregnancy meeting above inclusion criteria 3. Major congenital anomaly such as major structural deficit of the heart, lungs, or brain or aneuploidy 1. Mild renal abnormalities, clubfoot, isolated cleft lip/palate, etc. in the fetus are not a reason for exclusion 2. For a detailed list of major anomalies, see Table 3 - Major Fetal Anomalies / Congenital Malformations, below. Two or more minor anomalies observed together (see Table 2 - Minor Fetal Anomalies / Congenital Malformations) count as a "major" anomaly 3. Isolated 'soft markers' for aneuploidy (such as choroid plexus cysts, echogenic bowel, etc.) are not a reason for exclusion 4. If aneuploidy screening is performed, any aneuploidy screen positive test with a risk for aneuploidy greater than 1 in 25 without negative confirmatory definitive aneuploidy testing is reason for exclusion 4. Spanish speaking women 5. Women participating in other intervention-based studies |
Country | Name | City | State |
---|---|---|---|
United States | University of North Carolina Women's Hospital | Chapel Hill | North Carolina |
Lead Sponsor | Collaborator |
---|---|
University of North Carolina, Chapel Hill |
United States,
Anding JE, Röhrle B, Grieshop M, Schücking B, Christiansen H. Couple comorbidity and correlates of postnatal depressive symptoms in mothers and fathers in the first two weeks following delivery. J Affect Disord. 2016 Jan 15;190:300-309. doi: 10.1016/j.jad.2015.10.033. Epub 2015 Oct 28. — View Citation
Blasio PD, Camisasca E, Caravita SC, Ionio C, Milani L, Valtolina GG. THE EFFECTS OF EXPRESSIVE WRITING ON POSTPARTUM DEPRESSION AND POSTTRAUMATIC STRESS SYMPTOMS. Psychol Rep. 2015 Dec;117(3):856-82. doi: 10.2466/02.13.PR0.117c29z3. Epub 2015 Nov 23. — View Citation
Carver CS, Scheier MF, Weintraub JK. Assessing coping strategies: a theoretically based approach. J Pers Soc Psychol. 1989 Feb;56(2):267-83. — View Citation
Edwards B, Galletly C, Semmler-Booth T, Dekker G. Does antenatal screening for psychosocial risk factors predict postnatal depression? A follow-up study of 154 women in Adelaide, South Australia. Aust N Z J Psychiatry. 2008 Jan;42(1):51-5. — View Citation
Geronimus AT, Hicken M, Keene D, Bound J. "Weathering" and age patterns of allostatic load scores among blacks and whites in the United States. Am J Public Health. 2006 May;96(5):826-33. Epub 2005 Dec 27. — View Citation
Juul SH, Hendrix C, Robinson B, Stowe ZN, Newport DJ, Brennan PA, Johnson KC. Maternal early-life trauma and affective parenting style: the mediating role of HPA-axis function. Arch Womens Ment Health. 2016 Feb;19(1):17-23. doi: 10.1007/s00737-015-0528-x. Epub 2015 May 9. — View Citation
McDonald SW, Kingston D, Bayrampour H, Dolan SM, Tough SC. Cumulative psychosocial stress, coping resources, and preterm birth. Arch Womens Ment Health. 2014 Dec;17(6):559-68. doi: 10.1007/s00737-014-0436-5. Epub 2014 Jun 20. — View Citation
McEwen BS. Stress, adaptation, and disease. Allostasis and allostatic load. Ann N Y Acad Sci. 1998 May 1;840:33-44. Review. — View Citation
Meltzer-Brody S, Boschloo L, Jones I, Sullivan PF, Penninx BW. The EPDS-Lifetime: assessment of lifetime prevalence and risk factors for perinatal depression in a large cohort of depressed women. Arch Womens Ment Health. 2013 Dec;16(6):465-73. doi: 10.1007/s00737-013-0372-9. Epub 2013 Aug 1. — View Citation
Meshberg-Cohen S, Svikis D, McMahon TJ. Expressive writing as a therapeutic process for drug-dependent women. Subst Abus. 2014;35(1):80-8. doi: 10.1080/08897077.2013.805181. — View Citation
Oh W, Muzik M, McGinnis EW, Hamilton L, Menke RA, Rosenblum KL. Comorbid trajectories of postpartum depression and PTSD among mothers with childhood trauma history: Course, predictors, processes and child adjustment. J Affect Disord. 2016 Aug;200:133-41. doi: 10.1016/j.jad.2016.04.037. Epub 2016 Apr 20. — View Citation
Schulkin J, Gold PW, McEwen BS. Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load. Psychoneuroendocrinology. 1998 Apr;23(3):219-43. Review. — View Citation
Smyth JM, Hockemeyer JR, Tulloch H. Expressive writing and post-traumatic stress disorder: effects on trauma symptoms, mood states, and cortisol reactivity. Br J Health Psychol. 2008 Feb;13(Pt 1):85-93. doi: 10.1348/135910707X250866. — View Citation
* Note: There are 13 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent Participation in Writing Activity | The percentage of women who respond that they completed their assigned writing activity will be measured. | through study completion, an average of 7 months per participant and 2 years for entire study | |
Primary | Statistically significant improvement (reduction) in the Perceived Stress Scale Score | Psychological instrument used to measure one's perception of stress (score range 0-40) will be assessed before and after the assigned writing activity. Higher scores on the scale indicate a higher vulnerability for those with a high levels of perceived stress in their life. Prior studies have noted the average score for a female age 30-44 is approximately 14. | through study completion, an average of 7 months per participant and 2 years for entire study | |
Primary | Proportion of women with adverse perinatal outcomes | We will define adverse pregnancy outcomes as a composite of preterm birth <37 weeks, intrauterine growth restriction, preeclampsia, and placental abruption; outcomes will be compared between randomization groups | outcome will be ascertained at delivery | |
Primary | Change in pro-inflammatory biomarkers in maternal blood by randomization group | All women participating in the study will have a blood draw. Levels of stress biomarkers (e.g., interleukin-6) will be compared by randomization group | through study completion, an average of 7 months per participant and 2 years for entire study | |
Primary | Change in pro-inflammatory biomarkers in maternal blood by outcome | All women participating in the study will have a blood draw. Levels of stress biomarkers (e.g., interleukin-6) will be compared between women who develop the adverse perinatal outcome and those who do not | through study completion, an average of 7 months per participant and 2 years for entire study | |
Primary | Change in stress-related gene expression in maternal blood by randomization group | All women participating in the study will have a blood draw. We will evaluate gene expression of the CTRA gene panel (conserved transcriptional response to adversity gene panel) by randomization group | through study completion, an average of 7 months per participant and 2 years for entire study | |
Primary | Change in stress-related gene expression in maternal blood by outcome | All women participating in the study will have a blood draw. We will evaluate gene expression of the CTRA gene panel (conserved transcriptional response to adversity gene panel) by whether or not the patient developed the adverse perinatal outcome | through study completion, an average of 7 months per participant and 2 years for entire study | |
Secondary | Utilization of professional psychiatric care | proportion of women who initiate or continue therapy with professional psychiatric care provider | through study completion, an average of 7 months per participant and 2 years for entire study | |
Secondary | Stress related pathways gene expression - placental tissue - by randomization group | After delivery, we will evaluate whether there are differences in the conserved transcriptional response to adversity gene panel (CTRA gene panel) by randomization groups | through study completion, an average of 7 months per participant and 2 years for entire study | |
Secondary | Stress related pathways gene expression - placental tissue - by diagnosis of adverse perinatal outcome | After delivery, we will evaluate whether there are differences in the conserved transcriptional response to adversity gene panel (CTRA gene panel) by whether or not the patient developed the adverse perinatal outcome | through study completion, an average of 7 months per participant and 2 years for entire study | |
Secondary | Rate of preterm birth less than 37 weeks' gestation by randomization group | we will individually evaluate the outcomes of preterm birth <37 weeks, intrauterine growth restriction, preeclampsia, and placental abruption; outcomes will be compared between randomization groups | through study completion, an average of 7 months per participant and 2 years for entire study | |
Secondary | Rate of diagnosis of intrauterine growth restriction, using sex-specific curves, by randomization group | we will individually evaluate the outcomes of preterm birth <37 weeks, intrauterine growth restriction, preeclampsia, and placental abruption; outcomes will be compared between randomization groups | through study completion, an average of 7 months per participant and 2 years for entire study | |
Secondary | Rate of diagnosis of preeclampsia by randomization group | we will individually evaluate the outcomes of preterm birth <37 weeks, intrauterine growth restriction, preeclampsia, and placental abruption; outcomes will be compared between randomization groups | through study completion, an average of 7 months per participant and 2 years for entire study | |
Secondary | Rate of diagnosis of placental abruption by randomization group | we will individually evaluate the outcomes of preterm birth <37 weeks, intrauterine growth restriction, preeclampsia, and placental abruption; outcomes will be compared between randomization groups | through study completion, an average of 7 months per participant and 2 years for entire study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03249896 -
Web/Smartphone-based Lifestyle Coaching Program in Pregnant Women With Gestational Diabetes
|
N/A | |
Completed |
NCT06338254 -
Efficacy of Percussion Massage Therapy Applied to the Lower Extremity on Pain, Edema in Pregnant Women
|
N/A | |
Recruiting |
NCT04825093 -
Vitamin D Supplementarion in Pregnant Women at Risk and COVID-19
|
N/A | |
Completed |
NCT04739462 -
SMS Maama Project COVID-19
|
N/A | |
Recruiting |
NCT04519593 -
ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma
|
N/A | |
Recruiting |
NCT03313024 -
Berlin-Brandenburg Pregnancy Cohort
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06357962 -
Semi-permanent Acupuncture Effect on Cervical Ripening
|
N/A | |
Not yet recruiting |
NCT06430853 -
Psychobiological Interventions in Pregnancy
|
N/A | |
Not yet recruiting |
NCT03661749 -
Urinary Protein to Creatinine Ratio in Term Pregnant Women
|
N/A | |
Completed |
NCT02970721 -
Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
|
||
Completed |
NCT02191774 -
Medical Abortion up to 10 Weeks Gestation at Home
|
||
Completed |
NCT01322529 -
Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be
|
N/A | |
Completed |
NCT00746551 -
Intravenous Versus Oral Iron in Late Pregnancy: Results of Treatment
|
Phase 4 | |
Completed |
NCT00678080 -
Metformin Versus Insulin in Pregnant Women With Type 2 Diabetes
|
N/A | |
Completed |
NCT00634530 -
Impact of a Nutritional Intervention Program for Weight Control During Pregnancy
|
N/A | |
Completed |
NCT00197561 -
Partnership on Nutrition and HIV/AIDS Research in Tanzania: Exploratory Research Study on Selenium and HIV Infection
|
Phase 3 | |
Completed |
NCT05527327 -
Pannus Retraction for Ultrasound Evaluation of the Obese Gravida: A Pilot Study
|
N/A | |
Recruiting |
NCT05551078 -
Thrombophilia Screening After Severe IUGR
|
||
Recruiting |
NCT03100084 -
PREdelivery Placental Biomarkers- Pregnancy and Delivery Outcome
|